Short communications Oxidative polymorphism of debrisoquine is not related to human colo-rectal cancer

Summary. The oxidative polymorphism of debrisoquine (DBQ) has been determined in 89 patients with colo-rectal cancer and in 556 normal control subjects. Four patients and 34 controls, with a metabolic ratio > 12.6, were classified as poor metabolisers of DBQ (n. s.). No difference was found in the distribution of the frequencies of the MR of DBQ between patients and controls.